The anti-aging gene klotho plays an important role in Ca 2ϩ and phosphate homeostasis. Membrane-bound klotho is an essential coreceptor for fibroblast growth factor-23 and can be cleaved by proteases, including a disintegrin and metalloproteinase (ADAM)10 and ADAM17. Cleavage of klotho occurs at a site directly above the plasma membrane (␣-cut) or between the KL1 and KL2 domain (␤-cut), resulting in soluble full-length klotho or KL1 and KL2 fragments, respectively. The aim of the present study was to gain insights into the mechanisms behind klotho cleavage processes in the kidney. Klotho shedding was demonstrated using a Madin-Darby canine kidney cell line stably expressing klotho and human embryonic kidney-293 cells transiently transfected with klotho. Here, we report klotho expression on both the basolateral and apical membrane, with a higher abundance of klotho at the apical membrane and in the apical media. mRNA expression of ADAM17 and klotho were enriched in mouse distal convoluted and connecting tubules. In vitro ADAM/matrix metalloproteinase inhibition by TNF484 resulted in a concentration-dependent inhibition of the ␣-cut, with a less specific effect on ␤-cut shedding. In vivo TNF484 treatment in wild-type mice did not change urinary klotho levels. However, ADAM/matrix metalloproteinase inhibition did increase renal and duodenal mRNA expression of phosphate transporters, whereas serum phosphate levels were significantly decreased. In conclusion, our data show that renal cells preferentially secrete klotho to the apical side and suggest that ADAMs are responsible for ␣-cut cleavage.
klotho; a disintegrin and metalloproteinase 10; a disintegrin and metalloproteinase 17; klotho shedding; a disintegrin and metalloproteinase/matrix metalloproteinase inhibitor CA 2ϩ AND PHOSPHATE HOMEOSTASIS is a tightly regulated process involving several hormones. Klotho is emerging as a key factor in this process (5, 18, 51) . Initially, the klotho gene was discovered as an anti-aging gene, since lack of klotho in mice resulted in early aging and a premature death (23, 26) , whereas overexpression of klotho led to an increased lifespan (28) .
Klotho is a single-pass type 1 transmembrane protein consisting of two extracellular domains, which are the KL1 and KL2 subunits. Full-length klotho has potential enzymatic activity (30, 49) , and in the body, it exists in two forms, namely, membrane-bound and soluble klotho. Membrane-bound klotho is predominantly present in the renal distal convolution, consisting of the distal convoluted tubule (DCT) and connecting tubule (CNT), parathyroid glands, and choroid plexus in the brain (26, 31) . A key function of membrane-bound klotho is to act as an obligate cofactor for the fibroblast growth factor (FGF) receptor, thereby enabling binding and downstream signaling of FGF23 via the ERK1/2 MAPK pathway (27, 51) . In the kidney, binding of FGF23 to the receptor complex results in enhanced phosphate excretion via reduced expression of the Na ϩ -phosphate transporters NaPi-IIa and NaPiIIc (12) . Moreover, FGF23 signaling downregulates 1␣-hydroxylase [cytochrome P-450 (cyp)27b1] and upregulates 24-hydroxylase (cyp24a1), enzymes involved in 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ] production and breakdown, respectively, resulting in a decrease of systemic levels of 1,25(OH) 2 D 3 (2, 46) .
Membrane-bound klotho can be cleaved by "sheddases" at positions next to the transmembrane domain (␣-cut) or between the KL1 and KL2 subunits (␤-cut), resulting in soluble full-length klotho or KL1 and KL2 fragments, respectively ( Fig. 1) . Soluble klotho can be detected in the serum, urine, and cerebrospinal fluid (22) . In the urine, klotho stabilizes the transient receptor potential vanilloid (TRPV)5 Ca 2ϩ channel on the apical membrane, leading to increased Ca 2ϩ reabsorption in the kidney (1, 5, 33) . A disintegrin and metalloproteinase (ADAM)10 and ADAM17 proteins are also membranebound proteins and are widely expressed in the body (43) . They are related to matrix metalloproteinases (MMPs) and cleave several proteins from the plasma membrane, including TNF-␣ and EGF (10, 43) . Interestingly, ADAM10 and ADAM17 have been shown to be responsible for klotho shedding in vitro and ex vivo as well (6) .
However, the molecular mechanisms responsible for the shedding of klotho and the subsequent consequences on Ca 2ϩ and phosphate homeostasis remain unknown. The aim of the present study was, therefore, to characterize renal klotho protein expression and to elucidate the mechanisms through which klotho is shed by determining the effects of ADAM/MMP inhibition on klotho shedding in vitro and in vivo.
taker Europe, Verviers, Belgium) supplemented with 5% (vol/vol) FCS (PAA Laboratories, Linz, Austria), 2 mM L-glutamine (SigmaAldrich, Zwijndrecht, The Netherlands), 10 l/ml nonessential amino acids (PAA Laboratories), and 10 g/ml ciprofloxacin at 37°C in a humidity-controlled incubator with 5% (vol/vol) CO 2. Stable transfection of MDCK cells was performed with Metafectene Pro (Biontex Laboratories, Martinsried, Germany) and 2 g klotho-GFP pEGFP-N3 according to the manufacturer's guidelines. After 24 h, cells were trypsinized, divided over petri dishes, and cultured in medium containing 800 g/ml G418 (Life Technologies Europe, Bleiswijk, The Netherlands). After 10 days, individual colonies were selected by means of cloning rings. The GFP tag allowed immediate screening of klotho-positive clones based on GFP fluorescence, and one clone was used for the subsequent experiments. MDCK klotho-GFP cells were seeded at a density of 1.5 ϫ 10 5 cells/cm 2 and grown on permeable filter supports (0.4-m pore size, Corning, Lowell, MA) for 5 days. Confluence was confirmed by measuring electrical resistance above 2,240 ⍀·cm 2 . Immunocytochemistry. Immunocytochemistry was performed as previously described (32) . In brief, MDCK klotho-GFP cells were grown on permeable filter supports as stated above and subsequently fixed in 4% (wt/vol) paraformaldehyde (Sigma-Aldrich) in PBS. The primary antibody rat anti E-cadherin (1:100, Sigma-Aldrich) was used overnight at 4°C. For the secondary antibody, a corresponding goat anti-rat Alexa fluor 594-conjugated IgG was used (1:250, Invitrogen, Carlsbad, CA). Images were obtained with an Olympus FV1000 confocal laser scanning microscope using a ϫ60 oil-immersion objective. Enhanced GFP (EGFP) was excited with a 488-nm laser, and Alexa fluor 594 was excited with a 559-nm laser. Images were processed with ImageJA 1.45b (Fiji, open source software).
Collection and concentration of culture media. MDCK klotho-GFP cells were grown to confluence on permeable filter supports as described above. After 16 h of incubation in serum-free culture medium, media of six different filters were harvested from the apical side (0.5 ml) and basolateral side (1 ml). Protease inhibitors [1 g/ml pepstatin A (MP Biomedicals, Santa Anna, CA), 12.5 g/ml leupeptin (MP Biomedicals), 1 mM PMSF (Sigma-Aldrich)] were added, and media were centrifuged for 2 min at 200 g to remove the remaining cells. Subsequently, the supernatant was concentrated to equal volumes (65 l) using centrifugal filter units (Amicon Ultra-4, 10K, Millipore, Billerica, MA), according to the manufacturer's protocol and denatured in Laemmli buffer containing 100 mM DTT for 30 min at 37°C. Samples were subsequently subjected to SDS-PAGE.
SDS-PAGE and immunoblot analysis. Protein samples were applied to an 8% (wt/vol) acrylamide SDS-PAGE gel and blotted to a polyvinylidene difluoride membrane (Millipore). Immunoblots of media from cultured cells were incubated with rat anti-KL1 (1:2,500, KM2076), rat anti-KL2 [1:2,500, KM2119, kind gifts from Dr. Makoto Kuro-O (University of Texas Southwestern Medical School)] or rat anti-klotho (1:1,000, R&D, Minneapolis, MN). Immunoblots of cell lysate protein samples were incubated with rabbit anti-GFP [1:5,000 (8) ] as the primary antibody. As secondary antibodies, the appropriate peroxidase-conjugated goat anti-rat and goat anti-rabbit antibodies (Sigma-Aldrich) were used. Blots were enhanced using chemiluminescence (ECL, Pierce, Etten-Leur, The Netherlands) and analyzed using ChemiDoc XRS (Bio-Rad, Veenendaal, The Netherlands). Semiquantification of immunoblots was performed as previously described (21) .
Isolation of the DCT and CNT using complex object parametric analysis and sorting. 
Shown are the forward and reverse mouse primers of the several genes used in real-time PCR on kidney and duodenum mRNA. NaPi-IIa and NaPiIIc, type II Na ϩ -phosphate transporters a and c; Pit1 and Pit2, type III Na ϩ -phosphate transporters 1 and 2; Trpv5 and Trpv6, transient receptor potential vanilloid members 5 and 6; Cabp9K, calbindin-D9K; Cyp, cytochrome P-450; ADAM, a disintegrin metalloproteinase; BCRP, breast cancer resistance protein.
pH 7.4] through the heart. The kidneys were removed, minced, and digested in 1 mg/ml collagenase (Worthington Biochemical, Lakewood, NJ) and 2,000 U/ml hyaluronidase (Sigma-Aldrich) in Krebs buffer at 37°C for 15 min. Tubules between 40 and 100 m were selected based on GFP fluorescence by complex object parametric analysis and sorting (COPAS; Union Biometrica, Holliston, MA) (9, 35) . Whole kidney samples contained both GFP-selected and unselected tubules. Total RNA was isolated using TRIzol total RNA isolation agent (Invitrogen), treated with DNase (Promega, Madison, WI), and reverse transcribed using Moloney murine leukemia virus reverse transcriptase (Invitrogen) for 1.5 h at 37°C. Gene expression levels were determined by quantitative real-time PCR using SYBR green (Bio-Rad) on a CFX69 Bio-Rad analyzer. Gene expression was normalized for Gapdh expression levels and calculated according to the ⌬⌬C T method (where CT is threshold cycle). Primer sequences are shown in Table 1 .
Cell culture of human embryonic kidney-293 cells and TNF484 treatment. Human embryonic kidney (HEK)-293 cells were grown in DMEM (Biowhittaker Europe) containing 10% (vol/vol) FCS (Hyclone, Logan, UT), 2 mM L-glutamine (Sigma-Aldrich), and 10 l/ml nonessential amino acids (PAA Laboratories) at 37°C in a humiditycontrolled incubator with 5% (vol/vol) CO2. Cells were transiently transfected with mouse klotho-GFP pEGFP-N3 or empty vector pEGFP-N3 using polyethyleneimine (Brunschwig Chemie, Amsterdam, The Netherlands) with a DNA-to-polyethyleneimine ratio of 1:6. After 48 h of transfection, klotho-GFP expression was confirmed by GFP fluorescence. The pharmacological compound TNF484, dissolved in PBS (described as compound 5 in Ref. 25 , a kind gift of Novartis Pharma, Bern, Switzerland) was used as the ADAM and MMP inhibitor. In addition, a more specific ADAM10 inhibitor, GI254023X (Tocris Bioscience, Bristol, UK), was used. Cells were incubated overnight with varying doses of TNF484 or GI254023X in serum-free culture medium. Media were collected and concentrated to equal volumes as described above. Both media and protein cell lysate samples were denatured in Laemmli buffer containing 100 mM DTT for 30 min at 37°C. Samples were subsequently subjected to SDS-PAGE.
In vivo treatment of mice with TNF484. Wild-type male C57BL/6N mice (8 wk, n ϭ 10 mice/group) were purchased from Charles River. Animals were housed in a temperature-and light-controlled room with food and drinking water available ad libitum. Mice received two intraperitoneal injections at 12-h intervals with either 10 mg TNF484/kg body wt in PBS or 100 l PBS. The concentration of TNF484 used has been proven functional in previous studies (48, 50) . To collect 24-h urine, animals were housed in individual metabolic cages for 24 h immediately after the first injection. At the time of euthanization, mice were anesthetized with isoflurane and exsanguinated via the orbital sinus. Kidneys were isolated, decapsulated, subdivided, and snap frozen in liquid nitrogen. Duodenum segments were extracted, rinsed with PBS, divided into four sections, and snap frozen in liquid nitrogen. The ethics committee of Radboud University Nijmegen approved the animal experiments.
Urine and tissue analysis. Protease inhibitors [1 g/ml pepstatin A (MP Biomedicals), 1 mM PMSF (Sigma-Aldrich), and 12.5 g/ml leupeptin (MP Biomedicals)] were added to 25 l urine, and samples were centrifuged for 2 min at 400 g. Laemmli buffer containing 100 mM DTT was added to the supernatant, and samples were incubated for 30 min at 37°C. Kidney protein lysates were prepared as previously described (40) and subjected to SDS-PAGE. The following primary antibodies were used: rat anti-KL1 (1:2,500, KM2076), sheep anti-uromodulin (1:1,000, Biotrend, Köln, Germany), mouse anti-␤-actin (1:10,000, Sigma-Aldrich), and rabbit anti-p44/42 and rabbit anti-44/42 MAPK (1:1,000, Cell Signaling, Danvers, MA). Membrane fractions were isolated as previously described (41) . In brief, tissue was homogenized in lysis buffer [50 mM Tris·HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 1 mM Na 3VO4, 5 mM NaF, 5 mM ␤-glycerophosphate, 0.27 M sucrose, 0.1% (vol/vol) 2-mercaptoethanol, and protease inhibitors (1 tablet/10 ml buffer, Roche, Basel, Switzerland)] and centrifuged at 1,500 g for 5 min at 4°C. The supernatant was subsequently centrifuged at 100,000 g for 1 h at 4°C, and the pellet was washed in lysis buffer without 2-mercaptoethanol and again centrifuged at 100,000 g for 15 min at 4°C. The pellet was resuspended in lysis buffer containing 1% (vol/vol) Nonidet P-40 and 0.1% (vol/vol) 2-mercaptoethanol and centrifuged at 14,300 g for 10 min at 4°C, and the protein amount of the supernatant (membrane fraction) was quantified and analyzed by immunoblot analysis. Rabbit antiNaPi-IIa [1:2,500, kind gift of Dr. Jürg Biber (University of Zürich, Zurich, Switzerland)], rabbit anti-NaPi-IIc (1:500, LifeSpan BioSciences, Seattle, WA), and rabbit anti-Na ϩ ,K ϩ -ATPase ␣-subunit [1: 2,000, C356-M09 (24)] were used as primary antibodies. Coomassie blue staining was performed for 1 h at room temperature, and samples were subsequently destained for 30 min. Total RNA was isolated from the kidneys and duodenum as described above.
Analytic procedures. Serum and urine phosphate concentrations were determined by in-hospital services using automatic biochemical analyzers. A colorimetric assay kit was used to measure serum and urinary Ca 2ϩ concentrations (15) . Ca 2ϩ measurements were verified using a commercial serum standard (Precinorm U, Roche). Serum 1,25(OH)2D3 levels were analyzed with an 125 I-labeled 1,25(OH)2D3 radioimmunoassay (IDS, Scottsdale, AZ). Parathyroid hormone (PTH) was determined using a mouse PTH 1-84 ELISA kit (Immutopics, San Clemente, CA), and FGF23 was determined using a mouse COOH-terminal FGF23 ELISA (Immutopics).
Statistics. Values are expressed as means Ϯ SE. Differences between control and TNF484-treated mice were tested using a two-sided unpaired t-test. Differences were considered to be statistically significant when P Ͻ 0.05. Data of the semiquantification of the TNF484 dose-response immunoblot was analyzed with nonlinear regression. Analysis of the data sets was performed using GraphPad Prism (version 6.0).
RESULTS

Abundance of soluble klotho was elevated in apical media.
The subcellular localization of klotho was studied using a MDCK cell line stably expressing klotho-GFP. Klotho colocalized with E-cadherin, indicating basolateral localization, and an intense signal was seen at the cell junction ( Fig. 2A) . The signal from klotho-GFP expression showed a higher intensity on the apical plasma membrane compared with the basolateral membrane (Fig. 2B) . Soluble klotho was detected in media derived from the apical and basolateral sides of nonstimulated MDCK klotho-GFP cells (Fig. 2C) . The bands at 130 kDa represent full-length soluble klotho, whereas the bands at 70 kDa (left immunoblot) and 55 kDa (right immunoblot) depict KL1 and KL2, respectively. The remaining bands could be breakdown products of soluble klotho. Both full-length klotho and the smaller fragments KL1 and KL2 were more abundant in media collected from the apical side compared with the basolateral side.
Enrichment of klotho and ADAM17 mRNA in distal convolution. To examine whether ADAM10 and ADAM17 are localized with klotho in the kidney, their renal mRNA expressions were investigated. Klotho mRNA expression levels were significantly enriched in GFP-selected DCTs and CNTs compared with the whole kidney (Fig. 3A) . This was also the case for ADAM17, whereas ADAM10 mRNA was not significantly enriched in DCTs or CNTs. As a negative control, mRNA expression in CNT (relative to total kidney, fold change) * * * * * Fig. 3 . Expression of klotho with a disintegrin and metalloproteinase (ADAM)10 and ADAM17. A and B: expression levels of ADAM10, ADAM17, klotho, and breast cancer resistance protein (BCRP) mRNA in complex object parametric analysis and sorting-selected mouse kidney distal convoluted tubules (DCTs; A) and connecting tubules (CNT; B). Open bars represent the whole kidney; solid bars represent selected tubules based on GFP enrichment. Both klotho and ADAM17 expression were significantly increased in DCTs and CNTs compared with whole kidney samples, whereas ADAM10 was not enriched. The proximal marker BCRP was significantly lower in both DCTs and CNTs. Data are means Ϯ SE of at least four mice and are expressed as fold differences compared with nonselected tubules. *P Ͻ 0.05. 
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In vitro ADAM/MMP treatment decreased klotho shedding. The effect of ADAM/MMP inhibition on klotho shedding was examined in HEK-293 klotho-expressing cells. Two different inhibitors, the ADAM/MMP inhibitor TNF484 and the more specific ADAM10 blocker GI254023X (20) , were compared by semiquantitative analysis (Fig. 4, A-C) . Both inhibitors comparably decreased total soluble full-length klotho and the KL1 fragment, where only the highest concentration GI254023X significantly decreased the KL1 fragment. Neither TNF484 nor GI254023X treatment affected the total amount of cellular klotho (Fig. 4, A and D, bottom immunoblot) . Subsequently, dose-dependent inhibition by the more general inhibitor TNF484 was observed, which resulted in an IC 50 value of 0.3 M TNF484 for total soluble full-length klotho (Fig. 4E) . Furthermore, TNF484 dose dependently reduced the shedding of the soluble KL1 fragment, which represents the ␤-cut (Fig.  4D) . However, this was to a lesser extent compared with full-length klotho. Semiquantification with nonlinear regression revealed an unsaturated dose-response curve for KL1, and, therefore, the IC 50 value could not be calculated (Fig. 4F) .
TNF484 treatment did not affect urinary klotho expression in vivo.
To determine the effects of ADAM/MMP inhibition on klotho shedding in vivo, mice were administered TNF484 or PBS and were characterized after 24 h. No effects of TNF484 on body weight, diuresis, or food and water intake were observed (Table 2 ). To establish whether TNF484 influenced urinary excretion of soluble klotho levels, klotho was detected by immunoblot analysis. No differences in urinary klotho excretion were demonstrated between control and TNF484-treated mice (Fig. 5A) . Samples from klotho knockout mice were used as a negative control. Uromodulin was used as an expression control for urinary secreted proteins. Although klotho mRNA expression was slightly, albeit significantly, increased in the kidney, klotho protein abundance was not altered after TNF484 treatment (Fig. 5, B and C) .
Upregulated expression of phosphate transporters after TNF484 treatment. To identify the mechanism through which ADAM/MMP inhibition affects phosphate and Ca 2ϩ transport, mRNA expression of different transporters was determined in renal and intestinal tissues. In the kidney, NaPi-IIc mRNA expression was slightly increased in TNF484-treated mice (Fig. 6A) . Expression of NaPi-IIa and type III Na ϩ -dependent phosphate cotransporters Pit1 and Pit2 was not changed upon TNF484 treatment. In the duodenum, Pit1 and Pit2 were significantly increased (Fig. 6B) . With regard to calciotropic genes, there was no difference for TRPV5 (Fig. 6C) , calbindin-D 9k (CaBP 9K ), or calbindin-D 28K mRNA expression (data not shown), although in the duodenum both TRPV6 and CaBP 9K expression were increased (Fig. 6D) . Renal protein expression of NaPi-IIa and NaPi-IIc was not significantly different be- Values are means Ϯ SE of at least nine mice. Effects of 24-h treatment with 20 mg TNF484/kg body wt or PBS (control) on body weight, food and water intake, and diuresis in mice are shown. tween the control and TNF484-treated groups (Fig. 6E) . Of note, TNF484 treatment did not affect mRNA expression levels of ADAM10 and ADAM17 in the kidney or duodenum (data not shown). TNF484 treatment decreased serum phosphate in vivo. To investigate whether TNF484 treatment affected phosphate and Ca 2ϩ homeostasis, serum and urinary phosphate and Ca 2ϩ levels were measured. Interestingly, TNF484-treated mice showed a significant decrease in serum phosphate levels compared with control mice (Fig. 7A) . However, urinary phosphate excretion, serum Ca 2ϩ levels, or urinary Ca 2ϩ excretion were not affected by TNF484 treatment (Fig. 7, B-D) . To determine whether ADAM/MMP inhibition influenced renal vitamin D synthesis, mRNA expression levels of cyp27b1 and cyp24a1
were measured. As shown in Fig. 8A , a twofold increase of cyp27b1 mRNA expression was observed in the TNF484-treated group, whereas no significant difference in mRNA expression was detected for cyp24a1. In contrast, no difference was demonstrated in systemic 1,25(OH) 2 D 3 , PTH, or FGF23 levels between control and TNF484-treated mice (Fig. 8, B-D) . In addition, phosphorylated ERK1/2 in the kidney was not significantly affected by TNF484 treatment (Fig. 8E) .
DISCUSSION
The present study provides more insights into cellular klotho expression and molecular regulation of klotho shedding. In renal epithelial cells, klotho was present both at the apical and Coomassie blue Fig. 6 . Effect of TNF484 treatment on expression levels of various phosphate and Ca 2ϩ -related genes in the kidney and duodenum. A: fold mRNA expression levels in control mice (open bars) and TNF484-treated mice (solid bars). The Na ϩ -phosphate transporter NaPi-IIc was significantly increased in TNF484-treated mice compared with control mice, whereas NaPi-IIa and phosphate transporters Pit1 and Pit2 remained unaltered in the kidney. B: fold mRNA expression levels of duodenal Pit1 and Pit2. Both were significantly upregulated in TNF484-treated mice. C: renal mRNA expression levels of the Ca 2ϩ transporter transient receptor potential vanilloid (TRPV)5 was unaltered after TNF484 treatment. D: fold mRNA expression levels of duodenal Ca 2ϩ transporter TRPV6 and Ca 2ϩ -binding protein calbindin-D9k (CaBP9k). Both were significantly increased in TNF484-treated mice compared with control mice. E: immunoblots of NaPi-IIa, NaPi-IIc, and Na ϩ -K ϩ -ATPase expression in purified renal membrane fractions. Immunoblots were semiquantified and corrected for Na ϩ -K ϩ -ATPase. There were no significant differences between the two groups for NaPi-IIa and NaPi-IIc. Coomassie blue staining was used as a loading control. Data are means Ϯ SE of at least nine mice. *P Ͻ 0.05. basolateral membrane with an increased abundance of soluble klotho in the apical compartment. Moreover, ␤-cut shedding is likely performed by proteases different from ADAMs.
Our data indicate that klotho localizes at both the apical and basolateral membrane of renal epithelial cells with a higher abundance of membrane-bound klotho at the apical side. This is in agreement with a previous study (31) that showed comparable results with immunofluorescent images in mouse kidneys using a different antibody. Additionally, shed klotho protein was more apparent in media collected from the apical compartment. This suggests either increased shedding on the apical side or, as recently suggested by Hu et al. (17) , the transportation of basolaterally secreted klotho to the apical side via transcytosis. Previous studies have demonstrated soluble klotho in the prourine (22) , where it alters the plasma membrane expression of several transporters involved in Ca 2ϩ and phosphate regulation, including TRPV5, TRPV6, NaPi-IIa, and renal outer medullary K ϩ channel 1 (4, 5, 18, 33) . Interestingly, soluble klotho levels were lower in basolaterally collected media, suggesting minor shedding of klotho at the basolateral side or, as suggested above, transcytosis of soluble klotho to the apical side. The membrane of the permeable filter supports used in these experiments may have hindered basolateral shedding of klotho. Moreover, the catabolism of soluble klotho on the basolateral or apical side could be regulated, or the model influences klotho or ADAM polarity. Another explanation could be that the interaction of klotho with the FGF receptor on the basolateral membrane may prevent shedding of klotho. In addition, other organs could be a source for systemic soluble klotho, such as the brain and parathyroid glands (26, 31) .
Shedding of membrane-bound proteins, such as klotho, can be performed by proteases like ADAM10 and ADAM17 (6) . ADAMs are membrane-bound enzymes, and thus colocalization with klotho would be a prerequisite to enable protein cleavage (42) . Concerning ADAM17, Mulder et al. (38) showed ADAM17 to be present mainly in the distal convolution and in small amounts in the proximal tubule using in situ hybridization in the human kidney. We confirmed these data in mice, with an enrichment of ADAM17 mRNA in the distal convolution. ADAM10 mRNA was expressed at basal levels, although not enriched, in the distal convolution. This is in line with a previous study (45) demonstrating ADAM10 expression in the distal convolution and collecting duct. As both ADAM17 and klotho were enriched in the distal convolution, this suggests a more prominent role for ADAM17 in renal klotho shedding.
In the present study, we have shown the capability of ADAM/MMP inhibition to decrease klotho shedding in vitro. Interestingly, a dose-dependent effect of the general ADAM/ MMP inhibitor TNF484 as well as the ADAM10-specific inhibitor GI254023X was observed on shedding of the fulllength klotho protein. Both inhibitors decreased klotho shedding in a similar manner, implying that ADAM10 alone, at least in HEK-293 cells, plays an important role in klotho shedding. Previously, it has been shown that the pharmacological compound TNF484 could inhibit ADAM17 and MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13 in vitro (25, 50) , although it is unclear whether this blocker can also inhibit ADAM10. Shedding of the KL1 fragment, however, appeared to be less dependent of both inhibitors, which suggests that klotho is preferentially cleaved by another protease at the ␤-cut site. Recently, Chen et al. (7) discovered the cleavage site of the ␣-cut of klotho. The cleavage site for the ␤-cut or its responsible sheddase both remain to be identified.
TNF484 has been successfully applied in different in vivo studies, mainly for decreasing inflammatory cytokines, such as TNF-␣ (48, 50) . To address whether TNF484 is able to affect klotho shedding in vivo, soluble klotho in the urine was detected via immunoblot analysis. No differences were observed in urinary klotho abundance or renal klotho protein expression between the two groups. At present, it is impossible . E: immunoblots of ERK1/2 phosphorylation (top immunoblot) and total ERK1/2 (bottom immunoblot) in kidney lysates from control and TNF484-treated mice. Immunoblots were semiquantified and corrected for total ERK1/2 expression. There was no significant difference for ERK1/2 phosphorylation between groups. Bars are means Ϯ SE of at least nine mice. *P Ͻ 0.05.
to determine TNF484-induced effects on systemic klotho levels, since the reliability of currently available assays to measure systemic klotho levels are controversial (14) . Nevertheless, our in vitro data indicate that ADAM/MMP inhibition indeed has klotho-dependent effects. This difference could be explained due to a higher local concentration on cells in vitro compared with in vivo, since TNF484 is rapidly metabolized in serum (36) . Moreover, the in vivo system is obviously more complex to determine the effect of a specific compound, as compensatory mechanisms may occur. Interestingly, after TNF484 treatment, serum phosphate levels decreased, and there was a tendency toward increased urine phosphate excretion, implying renal phosphate wasting. Although increased levels of PTH or FGF23 would be expected, no differences in systemic levels were found for these hormones. ADAMs are known to shed a range of proteins, so klotho-independent effects could cause the lower serum phosphate level. Until now, the effect of TNF484 treatment on phosphate homeostasis in vivo has not been investigated (48, 50) . Moreover, mRNA levels of the renal phosphate transporter NaPi-IIc and duodenal transporters Pit1 and Pit2 were elevated in TNF484-treated mice. These data suggest that compensation mechanisms for the low serum phosphate levels have been initiated to increase renal and intestinal phosphate (re)absorption. In contrast to phosphate, no effects of TNF484 were observed on Ca 2ϩ homeostasis except for elevated duodenal TRPV6 and CaBP 9k mRNA expression. In addition, mRNA expression of the renal vitamin D-producing enzyme cyp27b1 was increased. A concomitant increase in serum 1,25(OH) 2 D 3 , levels was, however, not detected. It appears that changes in mRNA levels of several important genes tested in the present study were not (yet) translated into measurable metabolic changes. Effects of TNF484 treatment on bone remodeling were not taken into account, given the short duration of the experiment.
There are different ways of influencing klotho shedding, including regulation by ADAM proteins. This topic, however, is still poorly understood. It seems that upregulation of ADAM10 and ADAM17 is controlled by growth factors and proinflammatory cytokines, although most of the regulation takes place at the posttranslational level, such as cleavage of the propeptide (3, 34) . In addition, tissue inhibitors of metalloproteinases are central regulators as natural inhibitors of ADAM proteins (39) . It has been shown that soluble fulllength klotho has different functions in the body, such as electrolyte transporter modification, as described above, and inhibition of the Wnt signaling pathway (44) and a possible protective role in cardiovascular disease (19, 47) . The function and shedding mechanisms of the smaller fragments KL1 and KL2, however, are not known, and further research is necessary.
In conclusion, the present study provides evidence that ADAMs are candidates for shedding of renal full-length klotho and that proteins other than ADAMs or MMPs are likely responsible for shedding the ␤-cut site of klotho. As soluble klotho has many important functions throughout the body, identification of the enzymes responsible for the shedding of klotho may have potential therapeutic opportunities.
